This article is more than 5 years old. Information may no longer be current.
VIDEO: Hitraya gives update on Vectra DA research
Click Here to Manage Email Alerts
WASHINGTON — At the American College of Rheumatology Annual Meeting, Elena Hitraya, MD, PhD, chief medical officer of Crescendo Bioscience, spoke about the latest data on Vectra DA, a multi-biomarker blood test for rheumatoid arthritis disease activity that integrates the concentrations of 12 serum proteins associated with disease activity into a single objective score.
Among the four studies presented here is the examination of diurnal and daily variations of the multi-biomarker disease activity score in patients with rheumatoid arthritis (RA). Based on short-term variability in the biomarker among patients with stable RA tested serially with time, the minimally important difference in the score was 9 units and blood samples taken during normal office hours would not be expected to be impacted by a diurnal variation in the multi-biomarker disease activity score in normal patients.
Hitraya also spoke about the results of a population-based study on the biomarker-related risk for myocardial infarction and serious infection in patients with RA; the prediction of flare and sustained clinical remission after adalimumab withdrawal; and multi-biomarker disease activity score and prediction of radiographic progression in patients with early RA who are treated with methotrexate alone or with adalimumab.